IP Library Granted Patent US 7,166,453
Granted Patent B2
US 7,166,453 · App. 10/864,874 · Granted Jan 23, 2007

Polypeptide

Assignee: Danisco A/S
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,166,453
App. No.
10/864,874
Granted
Jan 23, 2007
Kind
B2
Abstract

We disclose a PS4 variant polypeptide derivable from a parent polypeptide, the parent polypeptide having non-maltogenic exoamylase activity, which PS4 variant polypeptide comprises one or more of the following substitutions: G69P, A141P, G223A, A268P, G313P, S399P and G400P, with reference to the position numbering of a Pseudomonas saccharophilia exoamylase sequence shown as SEQ ID NO: 1. Such PS4 variant polypeptides may be used as exo-amylases, particularly as non-maltogenic exoamylases. Combinations of such PS4 variant polypeptides together with Novamyl are disclosed.

Claims (24)

1. A PS4 variant polypeptide derivable from a parent polypeptide, the parent polypeptide having non-maltogenic exoamylase activity, which PS4 variant polypeptide comprises a proline substitution at position 141 with reference to the position numbering of a Pseudomonas saccharophilia exoamylase sequence shown as SEQ ID NO: 1, in which the PS4 variant polypeptide has at least 95% homology to SEQ ID NO: 1 and non-maltogenic exoamylase activity and a higher thermostability compared to the parent polypeptide when tested under the same conditions.

2. A PS4 variant polypeptide according to claim 1 , in which the parent polypeptide comprises a glucan 1,4-alpha-maltotetrahydrolase (EC 3.2.1.60).

3. A PS4 variant polypeptide according to claim 2 , in which the parent polypeptide is a non-maltogenic exoamylase of Pseudomonas saccharophilia or Pseudomonas stutzeri.

4. A PS4 variant polypeptide according to claim 3 , in which the parent polypeptide is a non-maltogenic exoamylase from Pseudomonas saccharophilia having a sequence shown as SEQ ID NO: 1.

5. A PS4 variant polypeptide according to claim 1 , in which the thermostability is measured by establishing a half life (t 1/2 ), at 60 degrees C.

6. A PS4 variant polypeptide according to claim 1 , which has a higher pH stability compared to the parent polypeptide when tested under the same conditions, wherein the pH is between pH5 to pH10.5.

7. A PS4 variant polypeptide according to claim 6 , which has 10% or more pH stability compared to the parent polypeptide, wherein the pH is between pH5 to pH10.5.

8. A PS4 variant polypeptide according to claim 1 , which further comprises an alanine substitution G223A.

9. A PS4 variant polypeptide according to claim 1 , which comprises a sequence PSac-A141P (SEQ ID NO: 3.

10. A PS4 variant polypeptide derivable from a parent polypeptide, the parent polypeptide having non-maltogenic exoamylase activity, which PS4 variant polypeptide comprises a proline substitution at position 141, or an alanine substitution at position 223, or both, with reference to the position numbering of a Pseudomonas saccharophilia exoamylase sequence shown as SEQ ID NO: 1, in which the PS4 variant polypeptide has at least 95% homology to SEQ ID NO:1 and non-maltogenic exoamylase activity and a higher thermostability compared to the parent polypeptide when tested under the same conditions.

11. A polypeptide sequence comprising a sequence of a non-maltogenic exoamylase which has been mutated to include a proline substitution at an amino acid position 141 or an alanine substitution at position 223, or both, with reference to a Pseudomonas saccharophilia exoamylase sequence shown as SEQ ID NO: 1.

12. A PS4 variant polypeptide according to claim 5 , in which the half life (t 1/2 ) at 60 degrees C. is increased by 15% or more relative to the parent polypeptide.

13. A PS4 variant polypeptide according to claim 5 , in which the half life (t 1/2 ) at 60 degrees C. is increased by 50% or more relative to the parent polypeptide.

14. A PS4 variant polypeptide according to claim 5 , in which the half life (t 1/2 ) at 60 degrees C. is increased by 100% or more relative to the parent polypeptide.

15. A PS4 variant polypeptide according to claim 1 , which has a higher activity compared to the parent polypeptide.

16. A PS4 variant polypeptide according to claim 15 , in which the activity is tested using a waxy maize starch incubation test.

17. A PS4 variant polypeptide according to claim 6 , which has 20% or more pH stability compared to the parent polypeptide.

18. A PS4 variant polypeptide according to claim 6 , which has 50% or more pH stability compared to the parent polypeptide.

19. A PS4 variant polypeptide according to claim 1 , in which the polypeptide is obtainable by altering the sequence of a parent polypeptide having non-maltogenic exoamylase activity, by introducing a proline substitution at position 141 with reference to the position numbering of a Pseudomonas saccharophilia exoamylase sequence shown as SEQ ID NO: 1 such that the polypeptide has a higher thermostability compared to the parent polypeptide when tested under the same conditions.

20. A polypeptide according to claim 19 , which is obtainable by altering the sequence of a nucleic acid which encodes the parent polypeptide.

21. A PS4 variant polypeptide derivable from a parent polypeptide, the parent polypeptide being a non-maltogenic exoamylase from Pseudomonas saccharophilia , the variant having a sequence shown as SEQ ID NO: 1 and non-maltogenic exoamylase activity and comprising a proline substitution at position 141, or a polypeptide which has at least 95% similarity thereto, non-maltogenic exoamylase activity and a proline residue at position 141.

22. A polypeptide obtainable by altering the sequence of a non-maltogenic exoamylase from Pseudomonas saccharophilia having a sequence shown as SEQ ID NO: 1, or a polypeptide which has at least 95% similarity thereto, by introducing a proline substitution at position 141.

23. A polypeptide according to claim 22 , which is obtainable by altering the sequence of a nucleic acid which encodes the non-maltogenic exoamylase from Pseudomonas saccharophilia.

24. A combination of a PS4 variant polypeptide according to any preceding claim, together with Novamyl, or a variant, homologue, or mutants thereof which has alpha amylase activity, or a composition comprising such.

Assignments (2)
CHANGE OF NAME Recorded Oct 26, 2012
From: DANISCO A/S
To: DUPONT NUTRITION BIOSCIENCES APS
Reel/Frame 029202/0953 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2004
From: KRAGH, KARSTEN MATTHIAS; PETERSEN, STEFFAN; MULDER, HARM; FOMSGAARD, HELLE; VELTMAN, ROBERT
To: DANISCO A/S
Reel/Frame 015301/0704 →
Priority Claims (1)
GB 0313754.4 · Jun 13, 2003 · national
Continuity (2)
Provisional Application 6047950500 · Jun 19, 2003
Related Publication 20050037391A1 · Feb 17, 2005